Table 2.
Age (years) | Prior lesion | WG at presentation | Symptoms |
Treatment |
|||||
---|---|---|---|---|---|---|---|---|---|
Headaches | Nausea | Visual disturbances | Hormonal replacement | Bromocriptine and cabergoline | Surgery | ||||
Kannuki et al.7 | 28 | PRL | 6 | + | + | ? | ? | ? | |
Ohtsubo et al.8 | 29 (multi) | AD | 24 | + | + | + | + | ||
Kita et al.9 | 26 (G1) | – | 26 | + | + | + | |||
Atmaca et al10 | 33 | MAD | 37 | + | + | + | + | ||
Luliano et al.11 | 28 | MAD | 29 | + | + | + | + | + | |
Gheorghiu et al.12 | 33 | AD | 22 | + | + | + | |||
Perotti et al.13 | 29 | – | 2 h PP | + | + | + | + | + | |
Schrupp et al.14 | 31 (G1) | – | 1 wk PP | + | + | − | |||
Jassal et al.15 | 32 (multi) | – | 4 days PP | + | + | + | |||
Freeman et al.16 | 22 | MAD | 32 | + | + | + | |||
Tonda et al.17 | 22 | – | 32 | + | + | + | |||
Krull et al.18 | 28 (G1) | – | 7 | + | + | ||||
O'Donovan et al.19 | 37 (multi) | MPRL | 8 | + | + | + | + | ||
Murao et al.20 | 35 | – | 39 | + | + | ||||
Nagulesparan et al. 21 | 34 | – | 31 | + | + | + | |||
Gondim et al.22 | 29 | MPRL | 30 | + | + | + | + | + | |
Zammit-Mangion et al.23 | 28 | – | 16 | + | + | + | |||
Zammit-Mangion et al.23 | 31 | - | 18 | + | + | + | |||
Onesti et al.24 | 28 | – | ? | + | + | + | |||
Hervet et al.25 | 26 | – | 24 | + | + | + | |||
Parihar et al.26 | 22 | MPRL | 20 | + | + | + | |||
Witek et al.27 | 25 (G1) | MPRL | 14 | + | + | + | + | ||
Scherrer et al.28 | ? | MAD | 16 | + | + | + | |||
Scherrer et al.28 | ? | mAD | 28 | + | + | + | |||
Lunardi et al.29 | 21 (multi) | – | 24 | + | + | + | |||
Fujimaki et al.30 | 23 (G1) | – | 24 | + | + | ||||
Ginath et al.31 | 31 (G1) | PRL | 39 | + | + | + | |||
Heide et al.32 | 26 (multi) | – | 23 | + | + | + | |||
Janssen et al.33 | 27 (G1) | – | 10 | + | + | + | + | ||
Bamfo et al.34 | 31 (G1) | – | 10 | + | + | + | |||
Lee et al.35 | 26 (G1) | – | 24 | + | + | + | + | ||
Lamberts et al.36 | 30 (G1) | PRL | 23 | + | + | + | + | ||
Rosen et al.37 | 32 | – | 22 | + | + | + | |||
Patients from the CHUM | |||||||||
Case 1 | 33 (G6) | – | 39 | + | + | − | − | – | − |
Case 2 | 30 (G1) | MPRL | 20 | − | − | − | − | + | − |
Case 3 | 37 (G1) | mPRL | 16 | + | + | + | − | + | − |
Case 4 | 40 (G4) | – | 6 h PP | + | − | − | + | − | − |
All 37 patients | 29a | 9 MAD (5 PRL) 5 mAD (4 MPRL) | 24 (4 PP) | 35/37 (95%) | 13/37 (35%) | 22/37 (59%) | 21/36 (58)% | 11/36 (31%) | 15/36 (42%) |
Median age.
Note: The treatment used in Kannuki's case6 was not specified, but we found the treatment in Ohtshubo's case7 in an English abstract. In total, treatments were specified for 36 patients. AD: adenoma non-specified; MAD: macroadenoma non-specified; mAD: microadenoma non-specified; PRL: prolactinoma; MPRL: macroprolactinoma; mPRL: microprolactinoma; GA: Gestational age; PP: postpartum; CHUM: Centre Hospitalier de l'Université de Montréal; WG: weeks of gestation.